Organisation paid for research Program year 2025 Source: CMS Open Payments

Clearview Medical Research

Neither a doctor nor a teaching hospital

Research payments

$418,213

22 payments

Through program year 2025, Clearview Medical Research is reported as receiving $418,213 in research payments, across 22 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $24,326 2
2024 Research $66,092 3
2023 Research $24,428 2
2022 Research $62,111 4
2021 Research $104,825 5
2020 Research $97,514 4
2019 Research $38,918 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $378,628 18 payments
  2. AstraZeneca UK Limited $39,586 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricemia $230,495 8 payments
  2. TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal $99,315 8 payments
  3. a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure $48,818 2 payments
  4. A Dose-Escalating Study in Children With Hyperkalaemia Between Birth and less than 18 Years of Age to Evaluate Increasing Doses of Sodium Zirconium Cyclosilicate (SZC) Given Three Times Daily for the Correction of Hyperkalaemia and the Effectiveness of the Same Dose of SZC Given Once Daily to Maintain Normokalaemia Among Those Requiring Continuous Treatment $32,883 2 payments
  5. A Phase II Randomized Multi Center Double Blind Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance Therapy in Patients whose Disease has not Progressed Following Standard of Care Platinum Based Chemotherapy with Durvalumab in First Line Stage IV Non Small Cell Lung Cancer ORION $6,703 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record